Drugs / CAR-γδT cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06196294 | May 2024 → Nov 2030 expected | liver cancer, lung cancer, malignant pancreatic neoplasm, mesothelioma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05388305 | Apr 2022 → Apr 2023 | acute myeloid leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR--γδT cells | “The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.” NCT06196294 ↗ |
| Modality | Cell therapy | “CAR-γδT cells” NCT05388305 ↗ |
| Route | Other | “transfer them back the patients via systemic or local injections” NCT06196294 ↗ |